Episode 5: Monitoring and Diagnostics in Chronic Myeloid Leukemia Episode 5: Monitoring and Diagnostics in Chronic Myeloid Leukemia
Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
September 27, 2023 -- On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Approves Bosutinib for Children With CML FDA Approves Bosutinib for Children With CML
The agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia
WEDNESDAY, Sept. 20, 2023 -- For patients with chronic myelogenous leukemia (CML) receiving tyrosine-kinase inhibitor therapy, exposure to dasatinib is associated with increased odds of proteinuria, according to a study published online in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news

Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes
(MedPage Today) -- HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL inhibitor ponatinib (Iclusig), a post... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 8, 2023 Category: Hematology Source Type: news

Episode 4: The Past, Present, and Future of Chronic Myeloid Leukemia Episode 4: The Past, Present, and Future of Chronic Myeloid Leukemia
Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

BTKi Combo Strong Option in CLL BTKi Combo Strong Option in CLL
A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Episode 3: Developments and Challenges in Chronic Myeloid Leukemia Episode 3: Developments and Challenges in Chronic Myeloid Leukemia
Drs Michael J. Mauro and Jorge E. Cortes discuss developments in the therapeutic landscape of chronic myeloid leukemia, complexities of resistance, and the potential for treatment-free remission.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

CAR-T cell therapy restores hope for leukemia patient
Jon Stahlecker had exhausted all treatment options and lost hope of surviving chronic lymphocytic leukemia (CLL) before Mayo Clinic offered him chimeric antigen receptor-T cell therapy (CAR-T cell therapy) in a clinical trial. "We got all our affairs in order. I was trying to see as many people and relatives as I could," says Stahlecker. "We had bought land to build a house but put that on hold. When you think you may only have… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 14, 2023 Category: Databases & Libraries Source Type: news

Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
(MedPage Today) -- The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 5, 2023 Category: Hematology Source Type: news

No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL
(MedPage Today) -- Patients with early-stage, high-risk chronic lymphocytic leukemia (CLL) failed to achieve an overall survival (OS) benefit when treated with ibrutinib (Imbruvica) compared with placebo, according to results from the randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 28, 2023 Category: Hematology Source Type: news

Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 23, 2023 Category: Pharmaceuticals Source Type: news

CLL: Venetoclax-Obinutuzumab Combo Effective Long Term CLL: Venetoclax-Obinutuzumab Combo Effective Long Term
Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

GM-CSF Inhibitor Lenzilumab Shows Early Promise in CMML GM-CSF Inhibitor Lenzilumab Shows Early Promise in CMML
Preliminary results from the PREACH-M trial show improvement in hematologic parameters in patients with RAS-mutant chronic myelomonocytic leukemia (CMML).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 19, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia
TUESDAY, June 13, 2023 -- Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukemia, including those with high risk features, according to a study published online June 7 in Clinical Cancer Research. John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 13, 2023 Category: Pharmaceuticals Source Type: news